Nebivolol Accord (Nebivolol Hydrochloride)

Nebivolol is a β1‑selective beta‑blocker used in cardiovascular therapy.

• Hypertension: lowers elevated blood pressure and reduces cardiovascular risk.
• Chronic heart failure: improves left‑ventricular function and alleviates symptoms in patients with systolic heart failure (where approved).
• Elderly hypertension: provides effective blood pressure control with a favorable tolerability profile in older adults.

• Nebivolol selectively antagonizes β1‑adrenergic receptors in cardiac tissue, reducing heart rate and contractility, which lowers cardiac output and blood pressure. In addition, it stimulates endothelial nitric oxide synthase, enhancing nitric oxide release and causing vasodilation, further contributing to its antihypertensive effect.

Common Side Effects

• Headache: mild to moderate headache may occur.
• Dizziness: often related to blood pressure reduction.
• Fatigue: a feeling of tiredness or reduced energy.
• Nausea: occasional gastrointestinal upset.
• Bradycardia: slower than normal heart rate.
• Peripheral edema: mild swelling of the ankles or feet.

Serious or Rare Side Effects

• Severe bradycardia: markedly low heart rate requiring medical attention.
• Symptomatic hypotension: significant drop in blood pressure causing faintness.
• Heart block: conduction abnormalities that may need intervention.
• Bronchospasm: especially in patients with reactive airway disease.
• Allergic reactions: rash, itching, or swelling.
• Hepatic dysfunction: abnormal liver enzyme elevations.

Nebivolol should be used with caution in specific clinical situations.

• Blood pressure monitoring: regularly assess to avoid excessive hypotension.
• Cardiac function assessment: evaluate heart rate and rhythm before and during therapy.
• Respiratory disease: use carefully in patients with asthma or COPD.
• Renal impairment: dose adjustment may be required in severe renal dysfunction.
• Discontinuation: avoid abrupt cessation; taper under medical supervision.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Nebivolol may interact with several medicines; monitoring is advised.

Major Interactions (Avoid)

• Other beta‑blockers: additive cardiac depression.
• Potent CYP2D6 inhibitors (e.g., paroxetine, quinidine): may increase nebivolol plasma levels.
• Non‑selective beta antagonists: risk of severe bradycardia.

Moderate Interactions (Monitor Closely):\n- Calcium channel blockers (verapamil, diltiazem): can enhance negative chronotropic effects.

• Diuretics: may potentiate hypotensive response.
• ACE inhibitors/ARBs: monitor for excessive blood pressure drop.
• NSAIDs: may reduce antihypertensive efficacy.
• Antiarrhythmic agents (e.g., amiodarone): observe for conduction disturbances.